Selected Publications

Academic Article

Year Title Altmetric
2019 Integrative Epigenetic and Gene Expression Analysis of Renal Tumor Progression to Metastasis.Cell Growth and Differentiation.  17:84-96. 2019
2018 Biochemical and Epigenetic Insights into L-2-Hydroxyglutarate, a Potential Therapeutic Target in Renal Cancer.Clinical Cancer Research.  24:6433-6446. 2018
2018 Wnt receptor Frizzled 8 is a target of ERG in prostate cancer.Prostate.  78:1311-1320. 2018
2017 Kinomic profiling identifies focal adhesion kinase 1 as a therapeutic target in advanced clear cell renal cell carcinoma.Oncotarget.  8:29220-29232. 2017
2016 Genetics of renal cancer: focus on MTOR.Aging.  8:421-422. 2016
2016 Kinase Gene Expression Profiling of Metastatic Clear Cell Renal Cell Carcinoma Tissue Identifies Potential New Therapeutic Targets.PLoS ONE.  11:e0160924. 2016
2015 Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.Oncotarget.  6:17895-17910. 2015
2015 Another small molecule in the oncometabolite mix: L-2-Hydroxyglutarate in kidney cancer.Oncoscience.  2:483-486. 2015
2015 High Throughput Kinomic Profiling of Human Clear Cell Renal Cell Carcinoma Identifies Kinase Activity Dependent Molecular Subtypes.PLoS ONE.  10:e0139267. 2015
2014 L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer.Cancer Discovery.  4:1290-1298. 2014
2014 The oncometabolite fumarate promotes pseudohypoxia through noncanonical activation of NF-κB signaling.Journal of Biological Chemistry.  289:24691-24699. 2014
2014 Do the sites of metastases provide additional information regarding prognosis and biology in renal cell carcinoma?European Urology.  65:585-586. 2014
2014 Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma.Expert Opinion on Investigational Drugs.  23:305-315. 2014
2013 The Proto-oncometabolite Fumarate Binds Glutathione to amplify ROS-dependent signalingMolecular Cell.  51:273. 2013
2013 The proto-oncometabolite fumarate binds glutathione to amplify ROS-dependent signaling.Molecular Cell.  51:236-248. 2013
2013 Stabilization of HIF-2α through redox regulation of mTORC2 activation and initiation of mRNA translation.Oncogene.  32:3147-3155. 2013
2013 PI3K regulation of the SKP-2/p27 axis through mTORC2.Oncogene.  32:2027-2036. 2013
2013 Metabolism of kidney cancer: from the lab to clinical practice.European Urology.  63:244-251. 2013
2012 Nox4 mediates renal cell carcinoma cell invasion through hypoxia-induced interleukin 6- and 8- production.PLoS ONE.  7:e30712. 2012
2011 Reduced expression of fumarate hydratase in clear cell renal cancer mediates HIF-2α accumulation and promotes migration and invasion.PLoS ONE.  6:e21037. 2011
2010 Increasing reactive oxygen species as a therapeutic approach to treat hereditary leiomyomatosis and renal cell carcinoma.Cell Cycle.  9:4183-4189. 2010
2010 Repeat partial nephrectomy on the solitary kidney: surgical, functional and oncological outcomes.Journal of Urology, The.  183:1719-1724. 2010
2009 Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species.Molecular and Cellular Biology.  29:4080-4090. 2009
2009 Renal cell carcinoma: recent advances in genetics and imaging.Seminars in Ultrasound, CT and MRI.  30:315-325. 2009
2008 Feasibility and outcomes of repeat partial nephrectomy.Journal of Urology, The.  180:89-93. 2008
2008 Salvage partial nephrectomy for hereditary renal cancer: feasibility and outcomes.Journal of Urology, The.  179:67-70. 2008
2007 Pseudohypoxic pathways in renal cell carcinoma.Clinical Cancer Research.  13:4667-4671. 2007
2007 HIF and fumarate hydratase in renal cancer.British Journal of Cancer.  96:403-407. 2007
2007 Mechanisms of disease: hereditary leiomyomatosis and renal cell cancer--a distinct form of hereditary kidney cancer.Nature Clinical Practice Urology.  4:104-110. 2007
2006 Genetic basis of cancer of the kidney.Seminars in Oncology.  33:544-551. 2006
2005 Abnormal fluorescence in situ hybridization analysis in collecting duct carcinoma.Urology.  66:1110. 2005
2005 In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer.Cancer Gene Therapy.  12:12-18. 2005
2003 Quantification and characterization of the bystander effect in prostate cancer cells following adenovirus-mediated FasL expression.Cancer Gene Therapy.  10:330-339. 2003
2002 Downregulation of c-FLIP sensitizes DU145 prostate cancer cells to Fas-mediated apoptosis.Cancer Biology and Therapy.  1:401-406. 2002
1999 Molecular analysis of the Cryptococcus neoformans ADE2 gene, a selectable marker for transformation and gene disruption.Experimental mycology.  27:36-48. 1999
1996 2-keto-3-deoxy-6-phosphogluconate aldolases as catalysts for stereocontrolled carbon-carbon bond formationJournal of the American Chemical Society.  118. 1996
1996 2-Keto-3-deoxy-6-phosphogluconate aldolases as catalysts for stereocontrolled carbon-carbon bond formationJournal of the American Chemical Society.  118:2117-2125. 1996
1973 Clinical trial with pyrantel pamoate (Combantrin) in ancylostomiasis.Journal of the Association of Physicians of India.  21:833-839. 1973

Investigator On

  • Private Grant  awarded by VIVENTIA BIO, INC. 2017 - 2022
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2017 - 2021
  • Private Grant  awarded by ASTELLAS PHARMA US, INC. 2017 - 2020
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2014 - 2019
  • UAB 1360: Immune Modulation by Addition of Oral Lenalidomide to Intravesical BCG (Bacille Calmette-Guerrin) for Therapy of Non-Muscle-Invasive Transitional Cell Bladder Cancer  awarded by H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE 2014 - 2019
  • Private Grant  awarded by ALTOR BIOSCIENCE CORPORATION 2015 - 2019
  • Registry for Treatment of Upper Urinary Tract Tumours: A Multi-Center, International Registry to Evaluate the Treatment of Upper Tract Urothelial Cancer (UTUC): Incidence, Indications, Treatment types and Outcomes  awarded by THE ENDOUROLOGY SOCIETY 2016 - 2017
  • A Phase II Exploratory, Randomized, Placebo-Controlled Trial of Pomegranate Fruit Extract (PFE/PomX) in Subjects with Clinically Localized Prostate Cancer Undergoing Active Surveillance  awarded by University of Wisconsin-Madison 2013 - 2016
  • A Specific Screening Strategy to Reduce Prostate Cancer Mortality  awarded by DOD - ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY 2012 - 2015
  • Private Grant  awarded by LEIDOS BIOMEDICAL RESEARCH, INC. 2013 - 2014
  • Tissue Resource Site (TSS) in Support of the The Cancer Genome Atlas (TCGA) Program - Admin Core  awarded by SAIC - FREDERICK 2013 - 2014
  • Education And Training

  • Doctor of Medicine, Duke University
  • Medical University of South Carolina Medical Cente, Residency 2005
  • Medical University of South Carolina Medical Cente, Residency 2002
  • National Cancer Institute, Postdoctoral Fellowship 2007
  • Full Name

  • Sunil Sudarshan